Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-07-02
2008-10-21
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S320100, C435S007100, C435S007200, C435S007210, C536S023100, C530S350000
Reexamination Certificate
active
07439039
ABSTRACT:
The serotonin transporter (SERT) is a target of various therapeutic agents used in the treatment of neurological and neurodegenerative disorders. The present invention provides novel forms of SERT that lacks high affinity recognition of specific serotonin reuptake inhibitors (SSRIs). The present invention therefore provides a novel target for use in screening and model development that can aid both the discovery of new medications and the discovery of novel pathways impacted in parallel with SERT blockade. Such novel targets can help identify new SSRI's with unique modifications and lead to discovery of pathways that secondarily support the therapeutic activity of these agents.
REFERENCES:
patent: 5418162 (1995-05-01), Blakely et al.
patent: 5552308 (1996-09-01), Hoffman et al.
patent: 5919797 (1999-07-01), Goodman et al.
patent: 6165716 (2000-12-01), Battersby et al.
patent: 2002/0142312 (2002-10-01), Cigler et al.
patent: 2003/0051266 (2003-03-01), Serafini
patent: WO 93/08261 (1993-04-01), None
patent: WO 97/11175 (1997-03-01), None
patent: WO 02/076204 (2002-10-01), None
Adkins et al., “Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition,” (abstract),Molecular Pharmacology, 59(3):514-523, 2001.
Barker and Blakeley, “Identification of a single amino-acid, phenylalanine-586, that is responsible for high-affinity interactions of tricyclic antidepressants with the human serotonin transporter,” (abstract),Molecular Pharmacology, 50(4):957-965, 1996.
Barker et al., “High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol,” (abstract),J. Biol. Chem., 273(31):19459-19468, 1998.
Barker et al., “Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter,” (abstract),J. Neurosci., 19(12):4705-4717, 1999.
Blakely and Bauman, “Biogenic amine transporters: regulation in flux,” (abstract),Curr. Opin. Neurobiol., 10(3):328-336, 2000.
Ewald et al., “A functional variant of the serotonin transporter gene in families with bipolar affective disorder,” (abstract),J. Affective Disorders, 48/2-3:134-144, 1998.
Guterrez et al., “Variability in the serotonin transporter gene and increased risk for major depression with melancholia,” (abstract),Hum Genet., 103(3):319-322, 1998.
Henry et al., “Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I,”J. Biol. Chem., 278(39):37052-37063, 2003.
Holmes et al., “Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter,” (abstract),Neuropsychopharmacology, 27(6):914-923, 2002.
Lin et al., “Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation,” (abstract),Biophysical Journal, 71(6):3126-3135, 1996.
Minov et al., “Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression,” (abstract),Neuroscience Letters, 303(2):119-122, 2001.
Mortensen et al., “Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants,” (abstract),J. Neurochemistry, 79(2):237-247, 2001.
Penado et al., “Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis,” (abstract),J. Biol. Chem., 273(43):28098-28106, 1998.
Ranganathan et al., “Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine,” (abstract),J. Neurosci., 21(16):5871-5884, 2001.
Roman et al., “Identification of serotonin transporter domains involved in the molecular recognition of cocaine and amphetamine,” (abstract), Society for Neuroscience Abstracts, 27(2):2154, 2001.
Sandhu et al., “A cocaine insensitive chimeric insect serotonin,” (abstract),European J. Biochem., 269(16):3934-3944, 2002.
Serretti et al., “Genetics of the response to antidepressants in mood disorders,”Giornale Italiano di Psicopatologia, 7/3:244-258, 2001.
Shen et al., “Refined mapping of the human serotonin transporter,” (abstract),Eur. J. Human Genetics, 8(1):75-78, 2000.
Smicun et al., “The role of external loop regionsi n serotonin transport-loop scanning mutagenesis of the serotonin transporter external domain,” (abstract),J. Biol. Chem., 274(51):36058-36064, 1999.
Sur et al., “A single serine residue controls the caption dependence of substrate transport by the rat serotonin transporter,” (abstract),Proc. Natl. Acad. Sci., USA, 94(14):7639-7644, 1997.
Sur et al., “The rat serotonin transporter: identification of cysteine residues important for substrate transport,” (abstract),Biochemical and Biophysical Research Communications, 241(1):68-72, 1997.
Chen and Rudnick, “Permeation and gating residues in serotonin transporter,”Proc. Natl. Acad. Sci., USA, 97(3):1044-1049, 2000.
Chen et al., “The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding,”J. Biol. Chem., 272(45):28321-28327, 1997.
Henry et al., “Identification of mutant serotonin transporters lacking high-affinity antidepressant interactions,”33rdAnnual Meeting of the Society of Neuroscience, Abstract No. 337.7, New Orleans, LA, Nov. 8-12, 2003.
Ramamoorthy et al., “Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization,”Proc. Natl. Acad. Sci., USA, 90:2542-2546, 1993.
Rudnick et al., “The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding,”Society for Neuroscience Abstracts, 23(1-2):404, 1997.
Schloss and Williams, “The serotonin transporter: a primary target for antidepressant drugs,”Journal of Psychopharmacology, 12(2):115-121, 1998.
Adkins Erika M.
Blakely Randy D.
Henry Loren Keith
Chernyshev Olga N
Fulbright & Jaworski LLP
Vanderbilt University
LandOfFree
Assays for novel serotonin transporter (SERT) blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays for novel serotonin transporter (SERT) blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays for novel serotonin transporter (SERT) blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992618